ZVSA

SEC source: 0001641172-25-019724 · ownership.xml · derivative · entry 1

Freitag Gregory Gene · CIK 0001492710 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,066

Underlying: Common Stock · 11,066 shares

Expires 2035-07-11

F1 · derivative.exercise_date: The options were granted on July 11, 2025, and vest and become exercisable in equal annual installments on the first three anniversaries of the grant date, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0001641172-25-019725 · ownership.xml · derivative · entry 1

Glover Stephen C. · CIK 0001304406 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 136,900

Underlying: Common Stock · 136,900 shares

Expires 2035-07-11

F1 · derivative.exercise_date: The options were granted on July 11, 2025, and vest and become exercisable in equal annual installments on the first three anniversaries of the grant date, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0001641172-25-019723 · ownership.xml · derivative · entry 1

Finizio Robert G · CIK 0001532235 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,066

Underlying: Common Stock · 11,066 shares

Expires 2035-07-11

F1 · derivative.exercise_date: The options were granted on July 11, 2025, and vest and become exercisable in equal annual installments on the first three anniversaries of the grant date, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0001641172-25-019728 · ownership.xml · derivative · entry 1

SAPIRSTEIN JAMES · CIK 0001559509 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,066

Underlying: Common Stock · 11,066 shares

Expires 2035-07-11

F1 · derivative.exercise_date: The options were granted on July 11, 2025, and vest and become exercisable in equal annual installments on the first three anniversaries of the grant date, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0001641172-25-019729 · ownership.xml · derivative · entry 1

Wolfe Peter · CIK 0001954398 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,100

Underlying: Common Stock · 60,100 shares

Expires 2035-07-11

F1 · derivative.exercise_date: The options were granted on July 11, 2025, and vest and become exercisable in equal annual installments on the first three anniversaries of the grant date, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0001641172-25-019726 · ownership.xml · derivative · entry 1

Guzman Pablo A. · CIK 0001963541 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,900

Underlying: Common Stock · 48,900 shares

Expires 2035-07-11

F1 · derivative.exercise_date: The options were granted on July 11, 2025, and vest and become exercisable in equal annual installments on the first three anniversaries of the grant date, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0001641172-25-019727 · ownership.xml · derivative · entry 1

Park Min-Chul · CIK 0001956022 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,066

Underlying: Common Stock · 11,066 shares

Expires 2035-07-11

F1 · derivative.exercise_date: The options were granted on July 11, 2025, and vest and become exercisable in equal annual installments on the first three anniversaries of the grant date, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0001641172-25-019858 · ownership.xml · derivative · entry 1

Cashmere Karen A. · CIK 0001954546 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,100

Underlying: Common Stock · 48,100 shares

Expires 2035-07-11

F1 · date: This Form 4 is being filed late as the result of an inadvertent administrative oversight.

F2 · derivative.exercise_date: The options were granted on July 11, 2025, and vest and become exercisable in equal annual installments on the first three anniversaries of the grant date, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0001493152-24-028399 · ownership.xml · derivative · entry 1

Freitag Gregory Gene · CIK 0001492710 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 132

Underlying: Common Stock · 132 shares

Expires 2033-05-24

F1 · date: The option disclosed on this Form 4 was not previously reported due to an administrative oversight.

F2 · shares: Share and dollar amounts give effect to the issuer's 1-for-35 reverse stock split effectuated on December 4, 2023, and 1-for-10 reverse stock split effectuated on April 25, 2024.

F3 · derivative.exercise_date: The option vests annually in three equal installments commencing on May 24, 2024.

SEC source: 0001493152-24-028404 · ownership.xml · derivative · entry 1

Glover Stephen C. · CIK 0001304406 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,627

Underlying: Common Stock · 1,627 shares

Expires 2033-05-24

F1 · date: The option disclosed on this Form 4 was not previously reported due to an administrative oversight.

F2 · shares: Share and dollar amounts give effect to the issuer's 1-for-35 reverse stock split effectuated on December 4, 2023, and 1-for-10 reverse stock split effectuated on April 25, 2024.

F3 · derivative.exercise_date: The option vests annually in three equal installments commencing on May 24, 2024.

SEC source: 0001493152-24-028402 · ownership.xml · derivative · entry 1

Finizio Robert G · CIK 0001532235 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 132

Underlying: Common Stock · 132 shares

Expires 2033-05-24

F1 · date: The option disclosed on this Form 4 was not previously reported due to an administrative oversight.

F2 · shares: Share and dollar amounts give effect to the issuer's 1-for-35 reverse stock split effectuated on December 4, 2023, and 1-for-10 reverse stock split effectuated on April 25, 2024.

F3 · derivative.exercise_date: The option vests annually in three equal installments commencing on May 24, 2024.

SEC source: 0001493152-24-028403 · ownership.xml · derivative · entry 1

SAPIRSTEIN JAMES · CIK 0001559509 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 132

Underlying: Common Stock · 132 shares

Expires 2033-05-24

F1 · date: The option disclosed on this Form 4 was not previously reported due to an administrative oversight.

F2 · shares: Share and dollar amounts give effect to the issuer's 1-for-35 reverse stock split effectuated on December 4, 2023, and 1-for-10 reverse stock split effectuated on April 25, 2024.

F3 · derivative.exercise_date: The option vests annually in three equal installments commencing on May 24, 2024.

SEC source: 0001493152-24-028400 · ownership.xml · derivative · entry 1

Cashmere Karen A. · CIK 0001954546 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 572

Underlying: Common Stock · 572 shares

Expires 2033-05-24

F1 · date: The option disclosed on this Form 4 was not previously reported due to an administrative oversight.

F2 · shares: Share and dollar amounts give effect to the issuer's 1-for-35 reverse stock split effectuated on December 4, 2023, and 1-for-10 reverse stock split effectuated on April 25, 2024.

F3 · derivative.exercise_date: The option vests annually in three equal installments commencing on May 24, 2024.

SEC source: 0001493152-24-028405 · ownership.xml · derivative · entry 1

Wolfe Peter · CIK 0001954398 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 715

Underlying: Common Stock · 715 shares

Expires 2033-05-24

F1 · date: The option disclosed on this Form 4 was not previously reported due to an administrative oversight.

F2 · shares: Share and dollar amounts give effect to the issuer's 1-for-35 reverse stock split effectuated on December 4, 2023, and 1-for-10 reverse stock split effectuated on April 25, 2024.

F3 · derivative.exercise_date: The option vests annually in three equal installments commencing on May 24, 2024.

SEC source: 0001493152-24-028401 · ownership.xml · derivative · entry 1

Park Min-Chul · CIK 0001956022 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 132

Underlying: Common Stock · 132 shares

Expires 2033-05-24

F1 · date: The option disclosed on this Form 4 was not previously reported due to an administrative oversight.

F2 · shares: Share and dollar amounts give effect to the issuer's 1-for-35 reverse stock split effectuated on December 4, 2023, and 1-for-10 reverse stock split effectuated on April 25, 2024.

F3 · derivative.exercise_date: The option vests annually in three equal installments commencing on May 24, 2024.

SEC source: 0001493152-23-002653 · ownership.xml · derivative · entry 1

Guzman Pablo A. · CIK 0001963541 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2033-01-26

F1 · derivative.exercise_date: The option vests in 3 equal annual installments commencing on January 26, 2024.

SEC source: 0001493152-22-035985 · ownership.xml · nonDerivative · entry 1

Wolfe Peter · CIK 0001954398 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,585

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.78 to $2.97 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.

SEC source: 0001493152-22-035483 · ownership.xml · derivative · entry 8

LaBella Nicholas A. Jr. · CIK 0001487698 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,094

Underlying: Common Stock · 18,094 shares

Expires 2027-12-12

F8 · derivative.exercise_date: The warrant is immediately exercisable in full.

SEC source: 0001493152-22-035483 · ownership.xml · derivative · entry 7

LaBella Nicholas A. Jr. · CIK 0001487698 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,781

Underlying: Common Stock · 29,781 shares

Expires 2032-01-28

F7 · derivative.exercise_date: The option vests in 3 equal annual installments commencing on January 28, 2023.

SEC source: 0001493152-22-035483 · ownership.xml · derivative · entry 6

LaBella Nicholas A. Jr. · CIK 0001487698 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,781

Underlying: Common Stock · 29,781 shares

Expires 2031-02-08

F6 · derivative.exercise_date: The option vests in 3 equal annual installments commencing on February 8, 2022.

SEC source: 0001493152-22-035483 · ownership.xml · derivative · entry 5

LaBella Nicholas A. Jr. · CIK 0001487698 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,708

Underlying: Common Stock · 39,708 shares

Expires 2029-04-02

F5 · derivative.exercise_date: 100% of the option is immediately exercisable. The option vested in 3 equal annual installments commencing on April 2, 2020.

SEC source: 0001493152-22-035483 · ownership.xml · derivative · entry 4

LaBella Nicholas A. Jr. · CIK 0001487698 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,563

Underlying: Common Stock · 59,563 shares

Expires 2027-10-30

F4 · derivative.exercise_date: 100% of the option is immediately exercisable. The option vested in 4 equal annual installments commencing on October 30, 2017.

SEC source: 0001493152-22-035483 · ownership.xml · derivative · entry 3

LaBella Nicholas A. Jr. · CIK 0001487698 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,709

Underlying: Common Stock · 39,709 shares

Expires 2025-06-09

F3 · derivative.exercise_date: 100% of the option is immediately exercisable. The option vested in 3 equal annual installments commencing on June 9, 2016.

SEC source: 0001493152-22-035483 · ownership.xml · derivative · entry 2

LaBella Nicholas A. Jr. · CIK 0001487698 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,854

Underlying: Common Stock · 19,854 shares

Expires 2024-04-11

F2 · derivative.exercise_date: 100% of the option is immediately exercisable. The option vested in 3 equal annual installments commencing on April 11, 2015.

SEC source: 0001493152-22-035483 · ownership.xml · nonDerivative · entry 1

LaBella Nicholas A. Jr. · CIK 0001487698 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,094

F1 · price: Received in connection with the Issuer's business combination with Larkspur Health Acquisition Corp., a Delaware corporation ("Larkspur") in accordance with the terms of the Business Combination Agreement, dated July 20, 2022, as amended (the "Business Combination Agreement") by and among ZyVersa Therapeutics, Inc., a Florida corporation ("Old ZyVersa"), the Securityholder Representative (as defined in the Business Combination Agreement) named therein, Larkspur, and Larkspur Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Larkspur ("Merger Sub") pursuant to which Merger Sub merged with and into Old ZyVersa (the "Acquisition Merger"), with Old Zyversa as the surviving company of the Acquisition Merger and, after giving effecting to such Acquisition Merger, Old ZyVersa became a wholly-owned subsidiary of Larkspur and changed its name to the Issuer.

SEC source: 0001493152-22-035479 · ownership.xml · derivative · entry 14

Glover Stephen C. · CIK 0001304406 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,750

Underlying: Common Stock · 1,750 shares

Expires 2027-12-12

F12 · price: The Reporting Person paid $1,000 per share of Series A Convertible Preferred Stock and warrants in an amount equal to 100% of the common shares issuable upon conversion of the Series A Convertible Preferred Stock for an aggregate of $17,500. No half shares of the Series A Convertible Preferred Stock were issued, therefore, the reporting person received 18 shares of such preferred stock instead of 17.5.

F11 · derivative.exercise_date: The warrant is immediately exercisable in full.

SEC source: 0001493152-22-035479 · ownership.xml · derivative · entry 13

Glover Stephen C. · CIK 0001304406 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 17,903

Underlying: Common Stock · 17,903 shares

Expires 2023-10-31

F11 · derivative.exercise_date: The warrant is immediately exercisable in full.

F2 · ownership.nature: The securities are held of record by Asclepius Life Sciences Fund, L.P ("ALS Fund"). Reporting Person serves as the managing member of ALS Fund. Reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0001493152-22-035479 · ownership.xml · derivative · entry 12

Glover Stephen C. · CIK 0001304406 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,022

Underlying: Common Stock · 3,022 shares

Expires 2023-10-31

F11 · derivative.exercise_date: The warrant is immediately exercisable in full.

SEC source: 0001493152-22-035479 · ownership.xml · derivative · entry 11

Glover Stephen C. · CIK 0001304406 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,881

Underlying: Common Stock · 70,881 shares

Expires 2027-12-12

F11 · derivative.exercise_date: The warrant is immediately exercisable in full.

SEC source: 0001493152-22-035479 · ownership.xml · derivative · entry 10

Glover Stephen C. · CIK 0001304406 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 79,417

Underlying: Common Stock · 79,147 shares

Expires 2032-02-03

F10 · derivative.exercise_date: The option vests in 3 equal annual installments commencing on January 28, 2023.

SEC source: 0001493152-22-035479 · ownership.xml · derivative · entry 9

Glover Stephen C. · CIK 0001304406 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 126,138

Underlying: Common Stock · 126,138 shares

Expires 2031-02-08

F9 · derivative.exercise_date: The option vests in 3 equal annual installments commencing on February 8, 2022.

SEC source: 0001493152-22-035479 · ownership.xml · derivative · entry 8

Glover Stephen C. · CIK 0001304406 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 264,838

Underlying: Common Stock · 264,838 shares

Expires 2029-04-02

F8 · derivative.exercise_date: 100% of the option is immediately exercisable. The option vested in 3 equal annual installments commencing on April 2, 2020.

SEC source: 0001493152-22-035479 · ownership.xml · derivative · entry 7

Glover Stephen C. · CIK 0001304406 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 168,761

Underlying: Common Stock · 168,761 shares

Expires 2026-10-28

F7 · derivative.exercise_date: 100% of the option is immediately exercisable. The option vested on October 28, 2016.

SEC source: 0001493152-22-035479 · ownership.xml · derivative · entry 6

Glover Stephen C. · CIK 0001304406 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 138,980

Underlying: Common Stock · 138,980 shares

Expires 2024-04-11

F6 · derivative.exercise_date: 100% of the option is immediately exercisable. The option vested in 3 equal annual installments commencing on April 11, 2015.

SEC source: 0001493152-22-035479 · ownership.xml · derivative · entry 5

Glover Stephen C. · CIK 0001304406 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,750

Underlying: Common Stock · 1,750 shares

Expires not disclosed

F12 · price: The Reporting Person paid $1,000 per share of Series A Convertible Preferred Stock and warrants in an amount equal to 100% of the common shares issuable upon conversion of the Series A Convertible Preferred Stock for an aggregate of $17,500. No half shares of the Series A Convertible Preferred Stock were issued, therefore, the reporting person received 18 shares of such preferred stock instead of 17.5.

F5 · derivative.expiration_date: The Series A Convertible Preferred Stock is perpetual and therefore has no expiration date.

SEC source: 0001493152-22-035479 · ownership.xml · nonDerivative · entry 4

Glover Stephen C. · CIK 0001304406 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 43,847

F1 · price: Received in connection with the Issuer's business combination with Larkspur Health Acquisition Corp., a Delaware corporation ("Larkspur") in accordance with the terms of the Business Combination Agreement, dated July 20, 2022, as amended (the "Business Combination Agreement") by and among ZyVersa Therapeutics, Inc., a Florida corporation ("Old ZyVersa"), the Securityholder Representative (as defined in the Business Combination Agreement) named therein, Larkspur, and Larkspur Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Larkspur ("Merger Sub") pursuant to which Merger Sub merged with and into Old ZyVersa (the "Acquisition Merger"), with Old Zyversa as the surviving company of the Acquisition Merger and, after giving effecting to such Acquisition Merger, Old ZyVersa became a wholly-owned subsidiary of Larkspur and changed its name to the Issuer.

F4 · ownership.nature: The securities are held of record by MedicaRx Inc. ("MRx"). Reporting Person serves as the managing director of MRx. Reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0001493152-22-035479 · ownership.xml · nonDerivative · entry 3

Glover Stephen C. · CIK 0001304406 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 49,636

F1 · price: Received in connection with the Issuer's business combination with Larkspur Health Acquisition Corp., a Delaware corporation ("Larkspur") in accordance with the terms of the Business Combination Agreement, dated July 20, 2022, as amended (the "Business Combination Agreement") by and among ZyVersa Therapeutics, Inc., a Florida corporation ("Old ZyVersa"), the Securityholder Representative (as defined in the Business Combination Agreement) named therein, Larkspur, and Larkspur Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Larkspur ("Merger Sub") pursuant to which Merger Sub merged with and into Old ZyVersa (the "Acquisition Merger"), with Old Zyversa as the surviving company of the Acquisition Merger and, after giving effecting to such Acquisition Merger, Old ZyVersa became a wholly-owned subsidiary of Larkspur and changed its name to the Issuer.

F3 · ownership.nature: The securities are held of record by Asclepius Master Fund, LTD. ("AM Fund"). Reporting Person serves as the managing director of AM Fund. Reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0001493152-22-035479 · ownership.xml · nonDerivative · entry 2

Glover Stephen C. · CIK 0001304406 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 85,442

F1 · price: Received in connection with the Issuer's business combination with Larkspur Health Acquisition Corp., a Delaware corporation ("Larkspur") in accordance with the terms of the Business Combination Agreement, dated July 20, 2022, as amended (the "Business Combination Agreement") by and among ZyVersa Therapeutics, Inc., a Florida corporation ("Old ZyVersa"), the Securityholder Representative (as defined in the Business Combination Agreement) named therein, Larkspur, and Larkspur Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Larkspur ("Merger Sub") pursuant to which Merger Sub merged with and into Old ZyVersa (the "Acquisition Merger"), with Old Zyversa as the surviving company of the Acquisition Merger and, after giving effecting to such Acquisition Merger, Old ZyVersa became a wholly-owned subsidiary of Larkspur and changed its name to the Issuer.

F2 · ownership.nature: The securities are held of record by Asclepius Life Sciences Fund, L.P ("ALS Fund"). Reporting Person serves as the managing member of ALS Fund. Reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0001493152-22-035479 · ownership.xml · nonDerivative · entry 1

Glover Stephen C. · CIK 0001304406 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 448,909

F1 · price: Received in connection with the Issuer's business combination with Larkspur Health Acquisition Corp., a Delaware corporation ("Larkspur") in accordance with the terms of the Business Combination Agreement, dated July 20, 2022, as amended (the "Business Combination Agreement") by and among ZyVersa Therapeutics, Inc., a Florida corporation ("Old ZyVersa"), the Securityholder Representative (as defined in the Business Combination Agreement) named therein, Larkspur, and Larkspur Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Larkspur ("Merger Sub") pursuant to which Merger Sub merged with and into Old ZyVersa (the "Acquisition Merger"), with Old Zyversa as the surviving company of the Acquisition Merger and, after giving effecting to such Acquisition Merger, Old ZyVersa became a wholly-owned subsidiary of Larkspur and changed its name to the Issuer.

SEC source: 0001493152-22-035477 · ownership.xml · derivative · entry 4

O'Connor Daniel J. · CIK 0001376847 · Director · 10% owner

Larkspur Health LLC · CIK 0001915818 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 177,204

Underlying: Common Stock · 177,204 shares

Expires 2027-12-12

F1 · kind: The Issuer completed a business combination with Larkspur Health Acquisition Corp., a Delaware corporation ("Larkspur") in accordance with the terms of the Business Combination Agreement, dated July 20, 2022, as amended (the "Business Combination Agreement") by and among ZyVersa Therapeutics, Inc., a Florida corporation ("Old ZyVersa"), the Securityholder Representative (as defined in the Business Combination Agreement) named therein, Larkspur, and Larkspur Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Larkspur ("Merger Sub") pursuant to which Merger Sub merged with and into Old ZyVersa (the "Acquisition Merger"), with Old Zyversa as the surviving company of the Acquisition Merger and, after giving effecting to such Acquisition Merger, Old ZyVersa became a wholly-owned subsidiary of Larkspur and changed its name to the Issuer.

F2 · kind: The securities were previously securities of Larkspur but were converted automatically to securities of the Issuer in connection with the transactions contemplated by the Business Combination Agreement.

F6 · derivative.exercise_date: The warrant is immediately exercisable in full.

F3 · ownership.nature: The securities are held of record by Larkspur Health LLC (the "Sponsor"). Daniel J. O'Connor is the sole manager of Larkspur Health LLC and in such capacity has voting and investment discretion with respect to the common stock held of record by Larkspur Health LLC. By virtue of this relationship, Mr. O'Connor may be deemed to have beneficial ownership of the securities held of record by the Sponsor. Mr. O'Connor disclaims any such beneficial ownership except to the extent of his pecuniary interest.

SEC source: 0001493152-22-035477 · ownership.xml · derivative · entry 3

O'Connor Daniel J. · CIK 0001376847 · Director · 10% owner

Larkspur Health LLC · CIK 0001915818 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,750

Underlying: Common Stock · 1,750 shares

Expires 2027-12-12

F1 · kind: The Issuer completed a business combination with Larkspur Health Acquisition Corp., a Delaware corporation ("Larkspur") in accordance with the terms of the Business Combination Agreement, dated July 20, 2022, as amended (the "Business Combination Agreement") by and among ZyVersa Therapeutics, Inc., a Florida corporation ("Old ZyVersa"), the Securityholder Representative (as defined in the Business Combination Agreement) named therein, Larkspur, and Larkspur Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Larkspur ("Merger Sub") pursuant to which Merger Sub merged with and into Old ZyVersa (the "Acquisition Merger"), with Old Zyversa as the surviving company of the Acquisition Merger and, after giving effecting to such Acquisition Merger, Old ZyVersa became a wholly-owned subsidiary of Larkspur and changed its name to the Issuer.

F2 · kind: The securities were previously securities of Larkspur but were converted automatically to securities of the Issuer in connection with the transactions contemplated by the Business Combination Agreement.

F5 · price: Mr. O'Connor paid $1,000 per share of Series A Convertible Preferred Stock and warrants in an amount equal to 100% of the common shares issuable upon conversion of the Series A Convertible Preferred Stock for an aggregate of $17,500. No half shares of the Series A Convertible Preferred Stock were issued, therefore, the reporting person received 18 shares of such preferred stock instead of 17.5.

F6 · derivative.exercise_date: The warrant is immediately exercisable in full.

SEC source: 0001493152-22-035477 · ownership.xml · derivative · entry 2

O'Connor Daniel J. · CIK 0001376847 · Director · 10% owner

Larkspur Health LLC · CIK 0001915818 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,750

Underlying: Common Stock · 1,750 shares

Expires not disclosed

F1 · kind: The Issuer completed a business combination with Larkspur Health Acquisition Corp., a Delaware corporation ("Larkspur") in accordance with the terms of the Business Combination Agreement, dated July 20, 2022, as amended (the "Business Combination Agreement") by and among ZyVersa Therapeutics, Inc., a Florida corporation ("Old ZyVersa"), the Securityholder Representative (as defined in the Business Combination Agreement) named therein, Larkspur, and Larkspur Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Larkspur ("Merger Sub") pursuant to which Merger Sub merged with and into Old ZyVersa (the "Acquisition Merger"), with Old Zyversa as the surviving company of the Acquisition Merger and, after giving effecting to such Acquisition Merger, Old ZyVersa became a wholly-owned subsidiary of Larkspur and changed its name to the Issuer.

F2 · kind: The securities were previously securities of Larkspur but were converted automatically to securities of the Issuer in connection with the transactions contemplated by the Business Combination Agreement.

F5 · price: Mr. O'Connor paid $1,000 per share of Series A Convertible Preferred Stock and warrants in an amount equal to 100% of the common shares issuable upon conversion of the Series A Convertible Preferred Stock for an aggregate of $17,500. No half shares of the Series A Convertible Preferred Stock were issued, therefore, the reporting person received 18 shares of such preferred stock instead of 17.5.

F4 · derivative.expiration_date: The Series A Convertible Preferred Stock is perpetual and therefore has no expiration date.

SEC source: 0001493152-22-035477 · ownership.xml · nonDerivative · entry 1

O'Connor Daniel J. · CIK 0001376847 · Director · 10% owner

Larkspur Health LLC · CIK 0001915818 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,377,598

F1 · kind: The Issuer completed a business combination with Larkspur Health Acquisition Corp., a Delaware corporation ("Larkspur") in accordance with the terms of the Business Combination Agreement, dated July 20, 2022, as amended (the "Business Combination Agreement") by and among ZyVersa Therapeutics, Inc., a Florida corporation ("Old ZyVersa"), the Securityholder Representative (as defined in the Business Combination Agreement) named therein, Larkspur, and Larkspur Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Larkspur ("Merger Sub") pursuant to which Merger Sub merged with and into Old ZyVersa (the "Acquisition Merger"), with Old Zyversa as the surviving company of the Acquisition Merger and, after giving effecting to such Acquisition Merger, Old ZyVersa became a wholly-owned subsidiary of Larkspur and changed its name to the Issuer.

F2 · kind: The securities were previously securities of Larkspur but were converted automatically to securities of the Issuer in connection with the transactions contemplated by the Business Combination Agreement.

F3 · ownership.nature: The securities are held of record by Larkspur Health LLC (the "Sponsor"). Daniel J. O'Connor is the sole manager of Larkspur Health LLC and in such capacity has voting and investment discretion with respect to the common stock held of record by Larkspur Health LLC. By virtue of this relationship, Mr. O'Connor may be deemed to have beneficial ownership of the securities held of record by the Sponsor. Mr. O'Connor disclaims any such beneficial ownership except to the extent of his pecuniary interest.

SEC source: 0001493152-22-035489 · ownership.xml · derivative · entry 3

Finizio Robert G · CIK 0001532235 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,927

Underlying: Common Stock · 9,927 shares

Expires 2032-01-28

F3 · derivative.exercise_date: The option vests in 3 equal annual installments commencing on January 28, 2023.

SEC source: 0001493152-22-035489 · ownership.xml · derivative · entry 2

Finizio Robert G · CIK 0001532235 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,854

Underlying: Common Stock · 19,854 shares

Expires 2031-02-08

F2 · derivative.exercise_date: The option vests in 3 equal annual installments commencing on February 8, 2022.

SEC source: 0001493152-22-035489 · ownership.xml · derivative · entry 1

Finizio Robert G · CIK 0001532235 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,781

Underlying: Common Stock · 29,781 shares

Expires 2029-04-02

F1 · derivative.exercise_date: 100% of the option is immediately exercisable. The option vested in 3 equal annual installments commencing on April 2, 2020.

SEC source: 0001493152-22-035487 · ownership.xml · derivative · entry 8

Wolfe Peter · CIK 0001954398 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,763

Underlying: Common Stock · 11,763 shares

Expires 2023-10-31

F7 · derivative.exercise_date: The warrant is immediately exercisable in full.

SEC source: 0001493152-22-035487 · ownership.xml · derivative · entry 7

Wolfe Peter · CIK 0001954398 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,058

Underlying: Common Stock · 18,058 shares

Expires 2027-12-12

F7 · derivative.exercise_date: The warrant is immediately exercisable in full.

SEC source: 0001493152-22-035487 · ownership.xml · derivative · entry 6

Wolfe Peter · CIK 0001954398 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,840

Underlying: Common Stock · 21,840 shares

Expires 2032-01-28

F6 · derivative.exercise_date: The option vests in 3 equal annual installments commencing on January 28, 2023.

SEC source: 0001493152-22-035487 · ownership.xml · derivative · entry 5

Wolfe Peter · CIK 0001954398 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,840

Underlying: Common Stock · 21,840 shares

Expires 2031-02-08

F5 · derivative.exercise_date: The option vests in 3 equal annual installments commencing on February 8, 2022.